- Conditions
- Solid Tumor
- Interventions
- PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 1,625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis Type 1, Precancerous Condition
- Interventions
- pirfenidone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Mocetinostat
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 11 more
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Not listed
- Lead sponsor
- Translational Genomics Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 80 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
- Interventions
- virtual bronchoscopy
- Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Cancer
- Interventions
- Palliative radiotherapy
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Sickle Cell Disease, Thalassemia, Pediatric Cancer
- Interventions
- Red Blood Cell (RBC) Transfusion
- Biological
- Lead sponsor
- Westat
- Other
- Eligibility
- Not listed
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Neurofibromatosis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 8 Years to 75 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Metastasis
- Interventions
- Chloroquine diphosphate
- Drug
- Lead sponsor
- Main Line Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma, Neuroblastoma, Wilms Tumor, Malignant Peripheral Nerve Sheath Tumor, Clival Chordoma, Non-CNS Solid Tumors
- Interventions
- HSV1716
- Biological
- Lead sponsor
- Timothy Cripe
- Other
- Eligibility
- 7 Years to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lynch Syndrome, Colorectal Cancer
- Interventions
- LS tumor screening, Genetic testing, Genetic Counseling, Biorepository, Questionnaire
- Genetic · Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 49
- States / cities
- Akron, Ohio • Barberton, Ohio • Batavia, Ohio + 29 more
- Conditions
- Neurofibromatosis 2, Meningioma
- Interventions
- AZD2014
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases
- Interventions
- Mirdametinib (MEK Inhibitor)
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Billerica, Massachusetts
- Conditions
- Tuberous Sclerosis
- Interventions
- JASPER
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 6 Months to 40 Months
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1, Cutaneous Neurofibromas
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Interventions
- FR901228
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Targeted Molecular Therapy, Tyrosine Kinase Inhibitor
- Drug · Biological · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2
- Interventions
- AR-42
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Cancer
- Interventions
- Oral cytobrushing
- Procedure
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Cancer
- Interventions
- BRCA1 and BRCA2
- Genetic
- Lead sponsor
- Data Collection Analysis Business Management
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Land O' Lakes, Florida
- Conditions
- Hereditary Cancer, Genetic Testing
- Interventions
- Relational agent (RA) / Chatbot, Enhanced Usual Care (EUC)
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 428 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • New Brunswick, New Jersey
- Conditions
- Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Portland, Oregon